secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001129928-26-000028
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC
--------------------------------------------------------------------------------

- Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.
- Objective response rate 33% with pelareorep+FOLFIRI+bevacizumab, tripling the 6-11% standard of care.
- Company actively engaging FDA to support potential accelerated approval pathway in this indication.
- REO 022 study continues enrollment in randomized Phase 2 for 2L RAS-mutant MSS mCRC.
- Data highlight durable benefit in a difficult-to-treat colorectal cancer population with few options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000028/0001129928-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000028/oncy-20260504.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer